Fig. 8

DAC and RSL3 synergistically have antileukemic effects in primary AML samples but not in normal HSPCs. (A) Cell viability was measured in 10 AML samples treated with Ctrl, DAC (1.0 µM) for 48 h, RSL3 (0.1 µM) for 24 h, or their combination in vitro. Each scatter plot represents mean value of one AML patient. (B and C) Cell viability was measured in two normal CD34⁺ HSPCs treated with Ctrl, DAC (1.0 µM) for 48 h, RSL3 (0.1 µM) for 24 h, or their combination. (D and E) Cell viability was measured in two CD34⁺ cells, which were isolated from two R/R AML patients, treated with Ctrl, DAC (1.0 µM) for 48 h, RSL3 (0.1 µM) for 24 h, or their combination. (F) MAGEA6 transcript levels were measured in four primary AML blasts treated with Ctrl or DAC (1.0 µM) for 48 h in vitro. (G and H) Overall survival was calculated in Ctrl (n = 6 for G and n = 5 for H), DAC (n = 6 for G and H), RSL3 (n = 6 for G and H), or DAC + RSL3 (n = 6 for G and H)-treated NSG mice transplanted with R/R AML cells. *P < 0.05; **P < 0.01; ***P < 0.001. N.S: not significant